Abstract Background The ONCO DVT study revealed the superiority of 12-month relative to 3-
month edoxaban treatment for cancer-associated isolated distal deep vein thrombosis (DVT) …

Background: The ONCO DVT (Edoxaban for 12 Months Versus 3 Months in Patients With
Cancer With Isolated Distal Deep Vein Thrombosis) study has revealed the superiority of a …

BACKGROUND: The optimal duration of anticoagulation therapy for isolated distal deep
vein thrombosis in patients with cancer is clinically relevant, but the evidence is lacking. The …

Background The multicenter, open-label, randomized clinical trial ONCO DVT compared 3-
month and 12-month edoxaban treatment regimens for isolated distal deep vein thrombosis …

Abstract Background The ONCO DVT study revealed superiority of 12-month relative to 3-
month edoxaban treatment for the thrombotic risk in cancer-associated isolated distal deep …

Background: The ONCO DVT study demonstrated potential benefits of extended edoxaban
treatment in patients with isolated distal deep vein thrombosis in terms of thrombotic risk …

Background: The efficacy and bleeding complications of direct oral anticoagulant (DOAC)
therapy for isolated distal deep vein thrombosis (IDDVT) associated with cancer in routine …

Background Isolated distal deep vein thrombosis (IDDVT) is the most common clinical
presentation of DVT. IDDVT in patients with cancer is often associated with a high risk of …

Introduction Few data exist on the use of edoxaban in cancer-associated venous
thromboembolism (VTE) outside of clinical trials. Aim of this study was to evaluate the …

Background: Although there are reports on the recurrence prevention in the chronic phase
using direct oral anticoagulants (DOACs) for deep vein thrombosis (DVT) in patients with …